Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Postoperative Pain and Functional Patient Outcomes After Functional Endoscopic Sinus Surgery

This study has been completed.
Hospira, now a wholly owned subsidiary of Pfizer
Information provided by (Responsible Party):
David R. Drover, Stanford University Identifier:
First received: June 23, 2009
Last updated: April 19, 2016
Last verified: April 2016
Results First Received: December 18, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Pain, Postoperative
Interventions: Drug: Bupivacaine Block
Drug: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Stanford medical center

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Having unilateral FESS

Reporting Groups
Group 1 - Bupivacaine Block Active treatment group with application of bupivacaine block before FESS.
Group 2 - Placebo Saline Block This group proceeded as per teh active treatment group but with blinded use of saline in the block syringe before start of FESS.

Participant Flow:   Overall Study
    Group 1 - Bupivacaine Block   Group 2 - Placebo Saline Block
STARTED   29   27 
COMPLETED   29   27 

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Group 1 Bupivacaine Active treatment group with application of bupivacaine block before FESS.
Group 2 - Saline Placebo Group Saline substituted in block, placebo treatment group with application of saline block before FESS.
Total Total of all reporting groups

Baseline Measures
   Group 1 Bupivacaine   Group 2 - Saline Placebo Group   Total 
Overall Participants Analyzed 
[Units: Participants]
 29   27   56 
[Units: Participants]
<=18 years   1   1   2 
Between 18 and 65 years   26   21   47 
>=65 years   2   5   7 
[Units: Years]
Mean (Full Range)
 (18 to 75) 
 (18 to 67) 
 (18 to 75) 
[Units: Participants]
Female   8   7   15 
Male   21   20   41 
Region of Enrollment 
[Units: Participants]
United States   29   27   56 

  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Postoperative Pain Assessed on Standard VAS Scale   [ Time Frame: VAS Pain Score at 7 days ]

2.  Secondary:   SNOT-20 Surgical Outcome Score   [ Time Frame: 1-day ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: David Drover, MD
Organization: Stanford University
phone: 6507250364

Publications of Results:

Responsible Party: David R. Drover, Stanford University Identifier: NCT00927888     History of Changes
Other Study ID Numbers: SU-05072009-2478
Study First Received: June 23, 2009
Results First Received: December 18, 2012
Last Updated: April 19, 2016